Recombinant Silk Elastin-like Protein Polymers for the Embolization of Cerebral Aneurysms

用于脑动脉瘤栓塞的重组丝弹性蛋白样蛋白聚合物

• 批准号: 9542385
• 负责人: Darwin Leroy Cheney
• 金额: $ 15万
• 依托单位: THERATARGET
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-15 至 2020-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9542385
• 关键词: Address; Aftercare; Aneurysm; Arteriovenous malformation; Biocompatible Materials; Biological Response Modifier Therapy; Blood; Blood flow; Brain hemorrhage; Catheters; Cell Therapy; Cells; Cerebral Aneurysm; Cerebrovascular system; Cessation of life; Characteristics; Chronic; Clinical; Development; Development Plans; Disease; Elastases; Elastin; Exposure to; Foreign Bodies; Formulation; Fracture; Functional disorder; Gel; Genetic; Genetic Engineering; Human; Hydrogels; Hypervascular; In Vitro; Inflammatory; Injectable; Injections; Instruction; Label; Lead; Liquid substance; Mechanics; Medical Care Costs; Metals; Modeling; Molecular Weight; Monitor; Neck; Nervous System Trauma; Neurologic Symptoms; Operative Surgical Procedures; Organic solvent product; Oryctolagus cuniculus; Paralysed; Performance; Peripheral; Pharmacotherapy; Phase; Physicians; Polymers; Polyvinyl Alcohol; Preparation; Protein Engineering; Proteins; Recombinant Proteins; Recombinants; Research; Risk; Rupture; Ruptured Aneurysm; Silk; Small Business Technology Transfer Research; Solid; Solubility; Structure; Symptoms; System; Testing; Therapeutic; Therapeutic Embolization; Thrombus; Tissues; Translating; Treatment Protocols; Vasculitis; Vasospasm; Wages; Work; aqueous; base; biomaterial compatibility; cerebral artery; cytotoxicity; design; healing; hemodynamics; improved; in vivo; in vivo Model; insight; iodixanol; local drug delivery; mechanical properties; metallicity; monomer; next generation; novel; pressure; prevent; response; risk minimization; seal; soft tissue; standard of care; tumor

NARRATIVE This STTR Phase I proposal details the rationale and the research plan for the development of a novel liquid embolizing agent composed of the genetically engineered protein polymer, SELP (silk-elastinlike protein)-815K, to embolize cerebral aneurysms. The SELP embolic would reduce the risk of aneurysm rupture while minimizing the risk of recanalization after treatment and providing a platform for delivering newly developed drugs or cell therapies directly to the aneurysmal sac. This work will result in an embolic that can potentially improve aneurysm healing, deliver therapeutics locally, and reduce the risks associated with the embolization of cerebral arteries.

叙事 本STTR第一阶段提案详细说明了开发新型液体的基本原理和研究计划 由基因工程蛋白质聚合物SELP（丝弹性蛋白样）组成的栓塞剂 蛋白质）-815K，栓塞脑动脉瘤。SELP栓塞可降低动脉瘤的风险 同时最大限度地降低治疗后再通的风险，并为输送 新开发的药物或细胞疗法直接作用于膀胱囊。这项工作将导致栓塞， 可以潜在地改善动脉瘤愈合，局部递送治疗剂，并降低与动脉瘤相关的风险。 脑动脉栓塞